| 3.31 -0.07 (-2.07%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.52 | 1-year : | 5.03 |
| Resists | First : | 3.87 | Second : | 4.3 |
| Pivot price | 3.62 |
|||
| Supports | First : | 3.18 | Second : | 2.64 |
| MAs | MA(5) : | 3.4 |
MA(20) : | 3.56 |
| MA(100) : | 3.13  |
MA(250) : | 2.6 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.7 |
D(3) : | 18.5 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 5.63 | Low : | 1.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IOVA ] has closed above bottom band by 10.8%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.39 - 3.42 | 3.42 - 3.44 |
| Low: | 3.2 - 3.24 | 3.24 - 3.27 |
| Close: | 3.26 - 3.33 | 3.33 - 3.37 |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Tue, 28 Apr 2026
Iovance (NASDAQ: IOVA) seeks approval to raise authorized common shares to 650M - Stock Titan
Tue, 28 Apr 2026
Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out (NASDAQ:IOVA) - Seeking Alpha
Mon, 27 Apr 2026
May 7 at 8:30 ET: Iovance to give Q1 results and updates - Stock Titan
Mon, 27 Apr 2026
Iovance Biotherapeutics to Report First Quarter 2026 - GlobeNewswire
Wed, 22 Apr 2026
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug - Yahoo Finance
Mon, 20 Apr 2026
Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 412 (M) |
| Shares Float | 353 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 110,830 (K) |
| Shares Short P.Month | 130,930 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | -148.4 % |
| Operating Margin | -84.7 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -55.5 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -302 (M) |
| Levered Free Cash Flow | -162 (M) |
| PE Ratio | -3.04 |
| PEG Ratio | 0 |
| Price to Book value | 1.94 |
| Price to Sales | 5.17 |
| Price to Cash Flow | -4.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|